Amanda Foster, NP
Nurse Practitioner · Shreveport, LANPI 1891473690
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,096, 4.4 times the $925 reported in 2023. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$995
- Amgen$857
- OPKO Pharmaceuticals, LLC$803
- Mallinckrodt Hospital Products Inc.$774
- AstraZeneca$766
- Travere Therapeutics, Inc.$695
- plus $4K from 19 others
What the payments were for
- Food & beverage$7,76891%
- Education$8039%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 45 | $995 |
| Amgen(2 entities) | 40 | $857 |
| OPKO Pharmaceuticals, LLC | 53 | $803 |
| Mallinckrodt Hospital Products Inc. | 43 | $774 |
| AstraZeneca(2 entities) | 35 | $766 |
| Travere Therapeutics, Inc. | 21 | $695 |
| Otsuka America Pharmaceutical, Inc. | 30 | $679 |
| Novartis | 32 | $673 |
| Fresenius USA Marketing, Inc. | 35 | $661 |
| Bayer | 27 | $455 |
| Boehringer Ingelheim | 19 | $332 |
| Novo Nordisk | 8 | $160 |
| ANI Pharmaceuticals, Inc. | 6 | $124 |
| Sanofi | 4 | $104 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $103 |
| Akebia Therapeutics Inc | 3 | $74 |
| Ardelyx, Inc. | 3 | $68 |
| Vifor Pharma, Inc. | 2 | $53 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Aurinia Pharma U.S., Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Medtronic | 1 | $26 |
| Recor Medical Inc | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,571 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 84 | $55,378 |
| JardianceEmpagliflozin | 29 | $31,841 |
| Cinacalcet Hcl | 76 | $20,884 |
| RayaldeeCalcifediol | 13 | $16,830 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $15,527 |
| KerendiaFinerenone | 22 | $14,951 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $12,177 |
| JanuviaSitagliptin Phosphate | 11 | $9,684 |
| InvokanaCanagliflozin | 12 | $7,880 |
| Calcitriol | 173 | $2,258 |
| Verapamil SrVerapamil Hcl | 11 | $1,575 |
| Hydralazine Hcl | 96 | $1,224 |
| Nifedipine ErNifedipine | 65 | $1,051 |
| Losartan Potassium | 140 | $1,050 |
| Potassium Chloride | 43 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $766 | $70,905107 claims |
| Boehringer IngelheimJardiance | $332 | $31,84129 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $803 | $16,83013 claims |
| BayerKerendia | $455 | $14,95122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.
Other nurse practitioner in Shreveport
- Tammy BennettShreveport$99K
- Sara BlankenshipShreveport$12K
- Gina InthavongShreveport$12K
- Valerie ScottShreveport$9K
- Deanna KamphuisShreveport$8K
- Amy LewingShreveport$7K
- Theresa StewartShreveport$7K
- Elizabeth WillisShreveport$7K
- Jacquline JansenShreveport$6K
- James HarrisShreveport$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.